Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Cancer Biology & Medicine
|
March 12, 2025
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma
Yi Wang, Yuting Yan, Dandan Shan, et al.
Scientific Reports
|
November 26, 2020
Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
Lanting Liu, Zhen Yu, Hui Cheng, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
May 10, 2025
A novel EndMT inhibitor, xanthotoxin, attenuates non-alcoholic fatty liver disease by acting as TGFβR2 antagonist
Xiaona Zhao, Fangjie Xia, Zixu Dong, et al.
Blood Science (Baltimore, Md.)
|
May 25, 2023
Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Ru Li, Tingyu Wang, Rui Lyv, et al.
Annals of Hematology
|
February 25, 2025
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
Yuting Yan, Yanshan Huang, Ying Yu, et al.
American Journal of Hematology
|
October 30, 2022
Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
Peiyu Yang, Haimin Chen, Xinyue Liang, et al.
American Journal of Cancer Research
|
March 14, 2025
Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma
Xinyue Liang, Weiling Xu, Fan Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
Wenqiang Yan, Chenxing Du, Rui Lv, et al.
Ebiomedicine
|
March 28, 2022
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
Zhen Yu, Xiaojing Wei, Lanting Liu, et al.
Annals of Hematology
|
April 19, 2022
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant
Yi Wang, Tingyu Wang, Ying Yu, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Cancer Biology & Medicine
|
March 12, 2025
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma
Yi Wang, Yuting Yan, Dandan Shan, et al.
Scientific Reports
|
November 26, 2020
Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
Lanting Liu, Zhen Yu, Hui Cheng, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
May 10, 2025
A novel EndMT inhibitor, xanthotoxin, attenuates non-alcoholic fatty liver disease by acting as TGFβR2 antagonist
Xiaona Zhao, Fangjie Xia, Zixu Dong, et al.
Blood Science (Baltimore, Md.)
|
May 25, 2023
Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Ru Li, Tingyu Wang, Rui Lyv, et al.
Annals of Hematology
|
February 25, 2025
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
Yuting Yan, Yanshan Huang, Ying Yu, et al.
American Journal of Hematology
|
October 30, 2022
Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
Peiyu Yang, Haimin Chen, Xinyue Liang, et al.
American Journal of Cancer Research
|
March 14, 2025
Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma
Xinyue Liang, Weiling Xu, Fan Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
Wenqiang Yan, Chenxing Du, Rui Lv, et al.
Ebiomedicine
|
March 28, 2022
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
Zhen Yu, Xiaojing Wei, Lanting Liu, et al.
Annals of Hematology
|
April 19, 2022
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant
Yi Wang, Tingyu Wang, Ying Yu, et al.
Page
of 6